Insiders Buy Shares of RxSight, Inc. (RXST)

Insiders at RxSight, Inc. (NasdaqGM: RXST), including Warner Robert Keith, purchased 37,037 shares on June 17, 2026. This move reflects a notable insider activity within the company.

Insider Buying and Selling at RxSight, Inc.

On June 17, several insiders, including Warner Robert Keith, Juliet Tammenoms Bakker, Robert Palmisano, William Link, Shweta Maniar, and Jesse Anderson Corley, each acquired 37,037 shares of RxSight, Inc. These transactions were not part of a pre-planned trading program.

Other Institutional Activity in RxSight, Inc.

In the broader institutional landscape, BlackRock, Inc. increased its holdings by 482,086 shares, now owning 3,187,092 shares valued at about $19.6 million. On the other hand, Millennium Management LLC reduced its position by 69,579 shares, holding 2,059,459 shares worth approximately $12.7 million. Artisan Partners Limited Partnership also trimmed its stake by 98,580 shares, ending with 2,058,684 shares valued at $12.7 million. Meanwhile, Nomura Holdings Inc. maintained its position with 2,000,060 shares valued at $12.3 million, and No Street GP LP added 25,000 shares, bringing its total to 2,000,000 shares worth $12.3 million.

RxSight, Inc. Stock Down 32.9%

Shares of RxSight, Inc. (NasdaqGM: RXST) are currently trading around $4.73. The company has a market capitalization of approximately $195.8 million. RxSight's stock has experienced a 52-week low of $4.48 and a high of $14.25. The stock's 50-day moving average is $6.09, while the 200-day moving average stands at $8.36. With a current ratio of 10.2 and a quick ratio of 8.779, RxSight maintains a strong liquidity position despite a debt-to-equity ratio of 4.05.

Recent Earnings

RxSight, Inc. reported revenue of $127.5 million, although it faced a revenue decline of 18.5%. The company has a negative net margin of 36.6% and a return on equity of -17.1%. The forward P/E ratio is not meaningful due to negative earnings per share of -$1.13. Investors are looking ahead to the next earnings report, expected on August 6, 2026.

Analysts Set New Price Targets

Analyst firms have recently weighed in on RxSight, Inc. On May 7, 2026, Wells Fargo maintained a 'hold' rating with a price target of $9.00, while Needham reiterated a 'buy' rating with a target of $11.00. The average analyst price target stands at $8.79, based on seven opinions.

About RxSight, Inc.

RxSight, Inc. is a healthcare company based in Aliso Viejo, California. It specializes in the development and sale of light adjustable intraocular lenses used in cataract surgery. The company's flagship product, the RxSight system, allows for customized visual acuity enhancements post-surgery through light adjustable lenses. Dr. Ronald M. Kurtz leads the company as its CEO, overseeing a team of 461 employees.

Bottom Line

The recent insider purchases at RxSight, Inc. highlight notable activity within the company as insiders, including Warner Robert Keith, increased their stakes. Investors often watch insider trades for potential insights into a company's prospects. With a market cap of $195.8 million and a challenging earnings environment, RxSight remains under analyst scrutiny, with a mean price target of $8.79. As always, remember that 13F filings and insider trades are backward-looking and may not reflect current positions.